Nautilus Biotechnology (NAUT) Competitors

$0.99 +0.04 (+3.84%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.56%)

As of 07:34 AM Eastern

NAUT vs. PACB, SLP, TKNO, LAB, and CDXS

Should you buy Nautilus Biotechnology stock or one of its competitors? Nautilus Biotechnology's main competitors and comparable companies include Pacific Biosciences of California (PACB), Simulations Plus (SLP), Alpha Teknova (TKNO), Standard BioTools (LAB), and Codexis (CDXS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Nautilus Biotechnology (NASDAQ:NAUT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Nautilus Biotechnology has higher earnings, but lower revenue than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Pacific Biosciences of California	$160.01M	3.07	-$546.38M	-$0.43	N/A

Nautilus Biotechnology presently has a consensus target price of $4.00, suggesting a potential upside of 303.84%. Pacific Biosciences of California has a consensus target price of $1.71, suggesting a potential upside of 8.39%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

In the previous week, Pacific Biosciences of California had 2 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 3 mentions for Pacific Biosciences of California and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.82 beat Pacific Biosciences of California's score of 1.03 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Pacific Biosciences of California	Positive

Nautilus Biotechnology has a net margin of 0.00% compared to Pacific Biosciences of California's net margin of -82.49%. Nautilus Biotechnology's return on equity of -37.58% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

50.7% of Nautilus Biotechnology shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nautilus Biotechnology has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

Summary

Nautilus Biotechnology beats Pacific Biosciences of California on 10 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Simulations Plus currently has a consensus target price of $17.25, suggesting a potential downside of 6.55%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 303.84%. Given Nautilus Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Nautilus Biotechnology is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Simulations Plus had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 6 mentions for Simulations Plus and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.82 beat Simulations Plus' score of 0.77 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Simulations Plus	Positive
Nautilus Biotechnology	Very Positive

Simulations Plus has a net margin of 9.88% compared to Nautilus Biotechnology's net margin of 0.00%. Simulations Plus' return on equity of 13.50% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Nautilus Biotechnology has lower revenue, but higher earnings than Simulations Plus. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.72	-$64.72M	$0.40	46.15
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Simulations Plus has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Summary

Simulations Plus beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Alpha Teknova?

Nautilus Biotechnology (NASDAQ:NAUT) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

Nautilus Biotechnology currently has a consensus price target of $4.00, suggesting a potential upside of 303.84%. Alpha Teknova has a consensus price target of $8.00, suggesting a potential downside of 13.89%. Given Nautilus Biotechnology's higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Alpha Teknova had 3 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 4 mentions for Alpha Teknova and 1 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 1.82 beat Alpha Teknova's score of 0.55 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Alpha Teknova	Positive

50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by insiders. Comparatively, 13.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Nautilus Biotechnology has a net margin of 0.00% compared to Alpha Teknova's net margin of -38.37%. Alpha Teknova's return on equity of -24.94% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Alpha Teknova	-38.37%	-24.94%	-16.53%

Alpha Teknova has higher revenue and earnings than Nautilus Biotechnology. Alpha Teknova is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Alpha Teknova	$40.52M	12.29	-$17.26M	-$0.31	N/A

Nautilus Biotechnology has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market.

Summary

Alpha Teknova beats Nautilus Biotechnology on 8 of the 15 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

In the previous week, Standard BioTools and Standard BioTools both had 1 articles in the media. Nautilus Biotechnology's average media sentiment score of 1.82 beat Standard BioTools' score of 1.79 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Very Positive
Nautilus Biotechnology	Very Positive

Nautilus Biotechnology has lower revenue, but higher earnings than Standard BioTools. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.42	-$74.90M	$0.22	3.38
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A

Standard BioTools has a net margin of 100.36% compared to Nautilus Biotechnology's net margin of 0.00%. Standard BioTools' return on equity of -7.57% beat Nautilus Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Nautilus Biotechnology	N/A	-37.58%	-30.83%

Standard BioTools has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Standard BioTools presently has a consensus target price of $1.35, suggesting a potential upside of 81.70%. Nautilus Biotechnology has a consensus target price of $4.00, suggesting a potential upside of 303.84%. Given Nautilus Biotechnology's stronger consensus rating and higher possible upside, analysts clearly believe Nautilus Biotechnology is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Standard BioTools beats Nautilus Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Nautilus Biotechnology compare to Codexis?

Nautilus Biotechnology (NASDAQ:NAUT) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Nautilus Biotechnology has a net margin of 0.00% compared to Codexis' net margin of -39.55%. Nautilus Biotechnology's return on equity of -37.58% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nautilus Biotechnology	N/A	-37.58%	-30.83%
Codexis	-39.55%	-74.36%	-23.58%

Codexis has higher revenue and earnings than Nautilus Biotechnology. Codexis is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.45	N/A
Codexis	$70.39M	2.13	-$43.97M	-$0.34	N/A

50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Nautilus Biotechnology currently has a consensus target price of $4.00, suggesting a potential upside of 303.84%. Codexis has a consensus target price of $6.50, suggesting a potential upside of 374.45%. Given Codexis' higher possible upside, analysts plainly believe Codexis is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nautilus Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Nautilus Biotechnology has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Codexis has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market.

In the previous week, Nautilus Biotechnology and Nautilus Biotechnology both had 1 articles in the media. Nautilus Biotechnology's average media sentiment score of 1.82 beat Codexis' score of 1.77 indicating that Nautilus Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Nautilus Biotechnology	Very Positive
Codexis	Very Positive

Summary

Codexis beats Nautilus Biotechnology on 7 of the 13 factors compared between the two stocks.

Get Nautilus Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAUT vs. The Competition

Export

Metric	Nautilus Biotechnology	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$127.18M	$10.51B	$7.31B	$13.29B
Dividend Yield	N/A	1.45%	2.52%	12.57%
P/E Ratio	-2.20	75.12	274.39	25.76
Price / Sales	N/A	110.26	685.35	111.79
Price / Cash	N/A	27.90	77.80	52.76
Price / Book	0.80	6.08	10.47	6.34
Net Income	-$59M	$56.67B	$3.49B	$360.00M
7 Day Performance	2.54%	3.11%	-0.91%	-0.18%
1 Month Performance	12.39%	3.18%	-4.21%	-4.09%
1 Year Performance	20.48%	40.73%	16.41%	5.97%

Nautilus Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAUT Nautilus Biotechnology	2.707 of 5 stars	$0.99 +3.8%	$4.00 +303.8%	+37.6%	$127.18M	N/A	N/A	130	Positive News
PACB Pacific Biosciences of California	1.2651 of 5 stars	$1.34 -0.7%	$1.71 +27.8%	+26.4%	$419.62M	$160.01M	N/A	485	Positive News
SLP Simulations Plus	0.8472 of 5 stars	$18.41 -0.1%	$17.25 -6.3%	+24.4%	$372.54M	$79.18M	46.03	213	News Coverage Positive News
TKNO Alpha Teknova	1.2621 of 5 stars	$6.90 +1.2%	$7.50 +8.7%	+63.8%	$365.65M	$40.52M	N/A	158
LAB Standard BioTools	3.9792 of 5 stars	$0.69 -0.9%	$1.35 +95.6%	-43.3%	$273.43M	$85.33M	3.14	389	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAUT) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. PACB, SLP, TKNO, LAB, and CDXS

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Summary

How does Nautilus Biotechnology compare to Simulations Plus?

Summary

How does Nautilus Biotechnology compare to Alpha Teknova?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Summary

How does Nautilus Biotechnology compare to Codexis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nautilus Biotechnology (NAUT) Competitors

NAUT vs. PACB, SLP, TKNO, LAB, and CDXS

How does Nautilus Biotechnology compare to Pacific Biosciences of California?

Which has higher earnings and valuation, NAUT or PACB?

Do analysts prefer NAUT or PACB?

Does the media prefer NAUT or PACB?

Is NAUT or PACB more profitable?

Do institutionals & insiders have more ownership in NAUT or PACB?

Which has more risk & volatility, NAUT or PACB?

Summary

How does Nautilus Biotechnology compare to Simulations Plus?

Do analysts recommend SLP or NAUT?

Does the media favor SLP or NAUT?

Is SLP or NAUT more profitable?

Which has better valuation and earnings, SLP or NAUT?

Do insiders and institutionals hold more shares of SLP or NAUT?

Which has more volatility & risk, SLP or NAUT?

Summary

How does Nautilus Biotechnology compare to Alpha Teknova?

Do analysts recommend NAUT or TKNO?

Does the media prefer NAUT or TKNO?

Do insiders and institutionals hold more shares of NAUT or TKNO?

Is NAUT or TKNO more profitable?

Which has preferable valuation and earnings, NAUT or TKNO?

Which has more risk and volatility, NAUT or TKNO?

Summary

How does Nautilus Biotechnology compare to Standard BioTools?

Does the media favor LAB or NAUT?

Which has higher valuation & earnings, LAB or NAUT?

Is LAB or NAUT more profitable?

Which has more volatility & risk, LAB or NAUT?

Do insiders & institutionals have more ownership in LAB or NAUT?

Do analysts prefer LAB or NAUT?

Summary

How does Nautilus Biotechnology compare to Codexis?

Is NAUT or CDXS more profitable?

Which has better earnings and valuation, NAUT or CDXS?

Do institutionals & insiders hold more shares of NAUT or CDXS?

Do analysts recommend NAUT or CDXS?

Which has more risk and volatility, NAUT or CDXS?

Does the media refer more to NAUT or CDXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAUT vs. The Competition

Nautilus Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools